Akiko Shimamura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Akiko Shimamura has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Alan D. D'ANdrea
From the Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA
1 shared publicationDavid G. Nathan
From the Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA
1 shared publicationJohn L. Svenson
From the Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA
1 shared publicationLisa A. Moreau
From the Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA
1 shared publicationNicholas Haining
From the Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA
1 shared publicationRocio Montes de Oca
From the Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA
1 shared publication
Latest Publications
- 15 December 2002
- Published by American Society of Hematology in Blood
- Vol. 100 (13) , 4649-4654
A novel diagnostic screen for defects in the Fanconi anemia pathway
Fanconi anemia (FA) is an autosomal recessive chromosomal instability syndrome characterized by congenital abnormalities, progressive bone marrow failure, and cancer predisposition. Although patients with FA are candidates for bone marrow transplantation or gene therapy, their phenotypic heterogeneity can delay or obscure diagnosis. The current diagnostic test for FA consists of cytogenetic quantitation of chromosomal breakage in response to diepoxybutane (DEB) or mitomycin C (MMC). Recent studies have elucidated a biochemical pathway for Fanconi anemia that culminates in the monoubiquitination of the FANCD2 protein. In the current study, we develop a new rapid diagnostic and subtyping FA assay amenable for screening broad populations at risk of FA. Primary lymphocytes were assayed for FANCD2 monoubiquitination by immunoblot. The absence of the monoubiquitinated FANCD2 isoform correlated with the diagnosis of FA by DEB testing in 11 known patients with FA, 37 patients referred for possible FA, and 29 healthy control subjects. Monoubiquitination of FANCD2 was normal in other bone marrow failure syndromes and chromosomal breakage syndromes. A combination of retroviral gene transfer and FANCD2 immunoblotting provides a rapid subtyping assay for patients newly diagnosed with FA. These new FA screening assays would allow efficient testing of broad populations at risk.
- 15 December 2002
- Published by American Society of Hematology in Blood
- Vol. 100 (13) , 4649-4654
A novel diagnostic screen for defects in the Fanconi anemia pathway
Fanconi anemia (FA) is an autosomal recessive chromosomal instability syndrome characterized by congenital abnormalities, progressive bone marrow failure, and cancer predisposition. Although patients with FA are candidates for bone marrow transplantation or gene therapy, their phenotypic heterogeneity can delay or obscure diagnosis. The current diagnostic test for FA consists of cytogenetic quantitation of chromosomal breakage in response to diepoxybutane (DEB) or mitomycin C (MMC). Recent studies have elucidated a biochemical pathway for Fanconi anemia that culminates in the monoubiquitination of the FANCD2 protein. In the current study, we develop a new rapid diagnostic and subtyping FA assay amenable for screening broad populations at risk of FA. Primary lymphocytes were assayed for FANCD2 monoubiquitination by immunoblot. The absence of the monoubiquitinated FANCD2 isoform correlated with the diagnosis of FA by DEB testing in 11 known patients with FA, 37 patients referred for possible FA, and 29 healthy control subjects. Monoubiquitination of FANCD2 was normal in other bone marrow failure syndromes and chromosomal breakage syndromes. A combination of retroviral gene transfer and FANCD2 immunoblotting provides a rapid subtyping assay for patients newly diagnosed with FA. These new FA screening assays would allow efficient testing of broad populations at risk.